Saturday 17 October 2026
Export TLX’s income statement to Excel — free account
Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024. Insiders bought in the last twelve months.
10.69
0.12
+1.14%
Follow TLX
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 1 |
Altman Z-Score |
— | 6.19 | 2.72 |
Altman Z″-Score (non-manufacturers) |
(0.16) | 3.04 | 0.88 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (1.79) | (1.57) |
P/B ratio |
0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 5.85 |
EV/FCF |
0.00 | 0.00 | 32.89 |
Quick Ratio |
1.14 | 2.57 | 1.17 |
Current Ratio |
1.41 | 2.78 | 1.43 |
Net Debt/EBITDA |
(4.71) | (1.35) | 6.25 |
Debt/Assets |
4.15% | 38.14% | 39.65% |
Debt/Equity |
0.11 | 1.02 | 1.11 |
Asset Turnover |
0.00 | 0.85 | 0.76 |
Operating CF/Net income |
4.58 | 0.82 | 2.43 |
Capex/Depreciation |
(1.60) | (4.20) | (2.04) |
Interest Coverage |
1.15 | 2.26 | 0.73 |
| 0.00% | 14.91% | (1.85%) | |
| 0.00% | 5.57% | (0.68%) | |
ROIC |
23.28% | 12.70% | 2.53% |
Return on Tangible Assets |
5.75% | 8.57% | (4.53%) |
Average Days of Receivables |
47.05 | 61.42 | 58.67 |
Research and Development Expense of Revenue |
25.58% | 24.77% | 21.31% |
Selling, General and Administrative Expense of Revenue |
26.70% | 30.58% | 29.50% |
Intangible Assets out of Total Assets |
0.27 | 0.27 | 0.51 |
Share Based Compensation of Revenue |
1.75% | 2.50% | 2.41% |
Graham Net Nets |
0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% |
Revenue per Share |
1.05 | 1.56 | 2.38 |
Operating CF per Share |
0.05 | 0.08 | (0.05) |
Capex per Share |
(0.02) | (0.07) | (0.13) |
Free Cash Flow per Share |
0.03 | 0.02 | (0.18) |
Cash per Share |
0.26 | 1.33 | 0.42 |
Shareholders Equity per Share |
0.31 | 1.07 | 1.23 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
0.31 | 1.07 | 1.23 |
Free Cash Flow |
8.70 | 5.31 | (61.07) |
Working Capital |
44.81 | 365.03 | 98.66 |
Capital Expenditures |
(7.17) | (22.18) | (43.78) |
Net Current Asset Value |
(16.31) | (17.32) | (418.33) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.02 | 0.04 | 0.05 |
| Other line items | |||
Depreciation/Fixed assets |
0.29 | 0.19 | 0.37 |
Cash ROIC |
4.53% | 0.46% | (5.99%) |
Accounts Receivable Turnover |
0.00 | 7.95 | 7.44 |
Accounts Payable Turnover |
0.00 | 2.56 | 3.18 |
Inventory Turnover |
0.00 | 10.27 | 12.43 |
Average Days of Payables |
158.50 | 175.61 | 145.43 |
Days of Inventory on Hand |
33.58 | 47.79 | 35.87 |
Average Receivables |
— | 64.98 | 108.07 |
Average Payables |
— | 70.54 | 118.57 |
Average Inventory |
— | 17.56 | 30.35 |
Average Assets |
— | 605.05 | 1,052.18 |
Average Common Equity |
— | 225.94 | 384.16 |
Columns are period end dates